Evropska unija - hrvaščina - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - virus ospica soj edmonston enders' (živa, progib), virusa паротита jeryl lynn u (razina b) soja (živa, progib), virus rubeole Вистар ra 27/3 soj (živa, progib) - rubella; mumps; immunization; measles - cjepiva - m-m-rvaxpro dizajniran za simultano cijepljenje protiv ospica, паротита i rubeole kod osoba od 12 mjeseci i stariji. za uporabu bljeskalice ospica, ili za постконтактной cijepljenja, ili za uporabu u prethodno непривитым djeca starija od 12 mjeseci koji dolaze u kontakt s osjetljiv trudnice, kao i osobe koje mogu biti izloženi паротита i rubeole.

Evropska unija - hrvaščina - EMA (European Medicines Agency)

medac gesellschaft fuer klinische spezialpraeparate mbh - asparaginaza - prekursorska stanica limfoblastične leukemije-limfom - antineoplastična sredstva - spectrila je indicirana kao komponenta antineoplastične kombinirane terapije za liječenje akutne limfoblastične leukemije (all) u pedijatrijskih bolesnika od rođenja do 18 godina i odraslih.

Evropska unija - hrvaščina - EMA (European Medicines Agency)

astrazeneca ab - selumetinib sulfate - neurofibromatosis 1 - antineoplastična sredstva - koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (pn) in paediatric patients with neurofibromatosis type 1 (nf1) aged 3 years and above.

Evropska unija - hrvaščina - EMA (European Medicines Agency)

janssen-cilag international n.v.    - amivantamab - karcinom, ne-malih stanica pluća - antineoplastična sredstva - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.

Evropska unija - hrvaščina - EMA (European Medicines Agency)

merck europe b.v. - tepotinib hydrochloride monohydrate - karcinom, ne-malih stanica pluća - antineoplastična sredstva - tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.

Evropska unija - hrvaščina - EMA (European Medicines Agency)

proveca pharma limited - enalapril (maleate) - zastoj srca - sredstva koja djeluju na sustav renin-angiotenzina - treatment of heart failure.

Evropska unija - hrvaščina - EMA (European Medicines Agency)

novo nordisk a/s - somapacitan - rast - hipofiza i hipotalamusni hormoni i analozi - sogroya is indicated for the replacement of endogenous growth hormone (gh) in children  aged 3  years and above, and adolescents with growth failure due to growth hormone deficiency (paediatric ghd), and in adults with growth hormone deficiency (adult ghd).

Evropska unija - hrvaščina - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - paklitaksela - breast neoplasms; pancreatic neoplasms; carcinoma, non-small-cell lung - antineoplastična sredstva - abraxane монотерапия indiciran za liječenje метастатического raka dojke kod odraslih pacijenata, koji ne prizemlju, kuhinju, blagovaonu-linija za obradu metastatic bolesti, a za koga standardni, антрациклин-sadrži terapija nije naveden. abraxane u kombinaciji s гемцитабин indiciran za prva linija terapije kod odraslih pacijenata s метастатической gušterače adenokarcinom gušterače. abraxane u kombinaciji s карбоплатином indiciran za prvu liniju liječenja немелкоклеточного raka pluća kod odraslih pacijenata koji nisu kandidati na potencijalno ljekovita kirurgije i/ili radioterapije.

Evropska unija - hrvaščina - EMA (European Medicines Agency)

bayer ag - finerenone - renal insufficiency, chronic; diabetes mellitus, type 2 - sredstva koja djeluju na sustav renin-angiotenzina - kerendia is indicated for the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults.

Evropska unija - hrvaščina - EMA (European Medicines Agency)

merck sharp & dohme b.v. - caspofungin (as acetate) - candidiasis; aspergillosis - antimikotika za sustavnu uporabu - treatment of invasive candidiasis in adult or paediatric patients;treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin b, lipid formulations of amphotericin b and / or itraconazole. refractoriness is defined as progression of infection or failure to improve after a minimum of seven days of prior therapeutic doses of effective antifungal therapy;empirical therapy for presumed fungal infections (such as candida or aspergillus) in febrile, neutropaenic adult or paediatric patients.